1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Leber’s Hereditary Optic Neuropathy - Drugs In Development, 2022, provides an overview of the Leber’s Hereditary Optic Neuropathy (Ophthalmology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Leber’s hereditary optic neuropathy (LHON) is an inherited form of vision loss. This condition usually begins in a person's teens or twenties, rare cases may appear in early childhood or later in adulthood. Males are affected much more often than females. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. Predisposing factors include age, tobacco smoke, alcohol, cancer treating drugs, stress related chemicals, some antibiotics and cyanogens.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Leber’s Hereditary Optic Neuropathy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Leber’s Hereditary Optic Neuropathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Leber’s Hereditary Optic Neuropathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 1, 1, 1, 1, 1, 9 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Leber’s Hereditary Optic Neuropathy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Leber’s Hereditary Optic Neuropathy (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Leber’s Hereditary Optic Neuropathy (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Leber’s Hereditary Optic Neuropathy (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Leber’s Hereditary Optic Neuropathy (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Leber’s Hereditary Optic Neuropathy (Ophthalmology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Leber’s Hereditary Optic Neuropathy (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Leber’s Hereditary Optic Neuropathy (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- REPORT COVERAGE
- Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Overview
- Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Companies Involved in Therapeutics Development
- Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Drug Profiles
- Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Dormant Projects
- Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Pipeline by Astellas Pharma Inc, 2022
- Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Pipeline by Biovista Inc, 2022
- Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Pipeline by Evvia Therapeutics Inc, 2022
- Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Pipeline by GenSight Biologics SA, 2022
- Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Pipeline by Imbria Pharmaceuticals Inc, 2022
- Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Pipeline by Ixchel Pharma LLC, 2022
- Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Pipeline by Metro International Biotech LLC, 2022
- Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Pipeline by Mitotech SA, 2022
- Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Pipeline by Neurophth Therapeutics Inc, 2022
- Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Pipeline by Neuroptika Inc, 2022
- Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Pipeline by PYC Therapeutics Ltd, 2022
- Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Pipeline by Stealth BioTherapeutics Corp, 2022
- Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Dormant Projects, 2022
List of Figures
- Number of Products under Development for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy), 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Astellas Pharma Inc
- Biovista Inc
- Evvia Therapeutics Inc
- GenSight Biologics SA
- Imbria Pharmaceuticals Inc
- Ixchel Pharma LLC
- Metro International Biotech LLC
- Mitotech SA
- Neurophth Therapeutics Inc
- Neuroptika Inc
- PYC Therapeutics Ltd
- Stealth BioTherapeutics Corp
